Our mission at Endpoints News is to provide readers a complete picture of the top drug development news of the day. And increasingly that means bringing fresh headlines from the biopharma revolution now fully underway in China. Which is why I’m pleased to announce a joint partnership with PharmCube — the leading data provider for the Chinese biopharma market.
Our collaboration focuses on two key areas, playing to each company’s strength.
First, Endpoints readers can expect more frequent analysis on Chinese therapies in development and the impact they represent. We’ll also feature occasional reports on the domestic commercial market as it continues to grow and on the evolution of the regulatory climate. That comes directly from access to their proprietary data and our investments in building out the editorial team over the past year.
And second, PharmCube is now Endpoints’ official syndicate in China, turbocharging our news distribution to Chinese biopharma readers through the PharmCube platform and social media channels.
We’ve long said that any biotech execs or companies that aren’t doing something about China will lose out to those that are. With this partnership, we’re deepening our own commitment to that and we look forward to bringing you the benefits.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 41,700+ biopharma pros who read Endpoints News by email every day.Free Subscription